Terminal phalangeal osteosclerosis and rheumatoid arthritis
- Erratum to: Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases. Nakagomi, Daiki; Ikeda, Kei; Kawashima, Hirotoshi; Kobayashi, Yoshihisa; Suto, Akira; Nakajima, Hiroshi // Rheumatology International;Oct2013, Vol. 33 Issue 10, p2707
A correction to the article "Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases" which was published in the September 11, 2013 issue is presented.
- Leg Ulcers Treated with Topical Tacrolimus in Patients with Rheumatoid Arthritis. Mandelin, Johanna M.; Eklund, Kari K.; Reitamo, Sakari // Acta Dermato-Venereologica;2010, Vol. 90 Issue 6, p633
The article presents case studies related to refractory rheumatic leg ulcers. An 84-year-old woman with seropositive rheumatoid arthritis (RA) for 24 years had one episode of acute bronchitis and one episode of cystitis during treatment. The ulcer of a 69-year-old woman with RA for 49 years was...
- Head-to-head study with RA drugs. // Australian Journal of Pharmacy;Jul2013, Vol. 94 Issue 1118, p30
The article focuses on the study ADalimumab ACTemrA (ADACTA)", which was published in the periodical "The Lancet," reveals that Actemra offers improvement in the signs and symptoms of rheumatoid arthritis (RA) for patients who require monotherapy as compared to adalimumab, as of July 1, 2013.
- Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Dcodhar, S. D.; Sethi, R.; Srimal, R. C. // Indian Journal of Medical Research;Jul2013, Vol. 138 Issue 1, p632
A short term, double blind, cross-over study was carried out in 18 patients with 'definite' rheumatoid arthritis to compare the antirheumatic activity of curcumin (diferuloyl methane) 1200 mg/day with phenylbutazone 300 mg/day. Subjective and objective assessment in patients who were not taking...
- The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Cai Yue; Xin You; Lidan Zhao; Haiyan Wang; Fulin Tang; Fengchun Zhang; Xuan Zhang; Wei He // Rheumatology International;Nov2010, Vol. 30 Issue 12, p1553
Objective of the study is to assess the effects of adalimumab and MTX therapy on peripheral Th17 cells and IL-17/IL-6 secretion in RA patients. Twenty active RA patients were treated with oral MTX 15 mg per week (MTX group, n = 10), or hypodermal adalimumab 40 or 80 mg every other week (ADA...
- Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis. Nishimura, Akito; Minegishi, Yohjiroh; Kwamura, Keiko; Ichino, Asako; Uchiyama, Katsufumi // Rheumatology International;Sep2015, Vol. 35 Issue 9, p1601
The article presents a case study of a 63-year-old woman who was diagnosed nephritis in her twenties and had polyarticular pain in her earlier. It mentions that she was diagnosed with rheumatoid arthritis (RA). Etanercept (ETN) was administrated as prednisolone did not improve her disease...
- Methotrexate. // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p195
An abstract of the article "Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report" by H. Shimada and others is presented.
- Genentech's ACTEMRA(r) Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy. // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1
The article presents information on the ADACTA (ADalimumab ACTemrA) study according to which patients receiving ACTEMRAÂ® (tocilizumab) experienced more decrease in disease activity after 24 weeks than those who were given adalimumab monotherapy. It is further mentioned that ADACTA study...
- Miscellaneous. // Current Medical Literature: Dermatology;2012, Vol. 17 Issue 1, p25
A review of the articles "Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis," by L. Bojke, "Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis," by D. H. Solomon and "The Ipswich Touch...